Wasel Akbary, DO
Internal Medicine · Fairfax, VANPI 1639189194
Payments from drug & device makers
Across 93 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$514
- Novo Nordisk$270
- Amgen$246
- AstraZeneca$116
- Pfizer$88
- Lilly USA, LLC$85
- plus $281 from 9 others
What the payments were for
- Food & beverage$1,599100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $514 |
| Novo Nordisk | 16 | $270 |
| Amgen | 16 | $246 |
| AstraZeneca | 8 | $116 |
| Pfizer | 5 | $88 |
| Lilly USA, LLC | 5 | $85 |
| Genentech USA, Inc. | 3 | $61 |
| Sanofi-aventis U.S. LLC | 3 | $54 |
| Amarin Pharma, Inc. | 2 | $44 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Scynexis, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
How this compares
$1,599 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 19 | $15,126 |
| JardianceEmpagliflozin | 15 | $14,539 |
| Memantine Hcl ErMemantine Hcl | 14 | $4,602 |
| Rosuvastatin Calcium | 79 | $1,950 |
| Travoprost | 11 | $1,715 |
| Valsartan | 47 | $1,705 |
| Tamsulosin Hcl | 31 | $707 |
| Atorvastatin Calcium | 70 | $594 |
| Losartan Potassium | 67 | $566 |
| Gabapentin | 25 | $492 |
| Esomeprazole Magnesium | 13 | $482 |
| Bupropion XlBupropion Hcl | 12 | $463 |
| Amlodipine Besylate | 50 | $417 |
| Pantoprazole Sodium | 19 | $401 |
| Escitalopram Oxalate | 19 | $401 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Fairfax
- Stanley StrickbergerFairfax$93K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.